Necrosis News and Research

RSS

Arthritis drugs used in children to be investigated because of cancer link

Authorities in the United States are investigating certain types of drugs used to treat arthritis and other conditions.

5 Jun 2008

Kidney cell suicide in diabetes patients

Diabetes is the leading cause of renal failure that requires dialysis. The disease generates such a hostile environment that it forces the kidney cells to kill themselves, progressively reducing the renal functions of the kidneys.

4 Jun 2008

Tuberculosis not the only risk from new immunological drugs

A new survey cautions physicians that drugs commonly prescribed for patients suffering from immunological disorders such as rheumatoid arthritis and inflammatory bowel disease may carry risks of serious infections other than the known risk of tuberculosis. The survey published is in the June 1 issue of Clinical Infectious Diseases, currently available online.

20 May 2008

Men at increased risk of death from pneumonia compared to women

Men who come to the hospital with pneumonia generally are sicker than women and have a higher risk of dying over the next year, despite aggressive medical care, according to a study being presented Tuesday, May 20, at the 104th International Conference of the American Thoracic Society. Scientific sessions are scheduled May 16 to 21 in Toronto.

19 May 2008

Researchers who helped millions with arthritis receive Janssen Award

Two British researchers who pioneered treatments which have helped millions of people with rheumatoid arthritis and other autoimmune diseases have been awarded the prestigious 2008 Dr. Paul Janssen Award for Biomedical Research, announced today.

13 May 2008

Study affirms effectiveness of medication for juvenile rheumatoid arthritis

Juvenile rheumatoid arthritis (JRA) is a chronic autoimmune disease that strikes children between the ages of newborn to 16 years. All children with JRA have joint pain, stiffness, and swelling and some also have fever and skin rashes.

9 May 2008

New tool for tissue damage assessment

A tool with the potential to determine the level of tissue damage in patients with osteo-arthritis, sports injuries and other conditions affecting bone and cartilage is being developed by QUT researchers. Professor Oloyede said that the device, which he calls a "smarthroscope", may be able to reduce the cost of surgery, eliminate unnecessary surgery, and could be useful in developing countries.

2 May 2008

Biomarkers identified for idiopathic pulmonary fibrosis

The first evidence of a distinctive protein signature that could help to transform the diagnosis and improve the monitoring of the devastating lung disease idiopathic pulmonary fibrosis (IPF) is being reported by University of Pittsburgh School of Medicine researchers in this month's edition of PLoS Medicine, an open-access journal of the Public Library of Science.

28 Apr 2008

FDA approves Cimzia as treatment for Crohn's disease

A new drug has been approved to help sufferers of Crohn's disease, the U.S. Food and Drug Administration announced today. Cimzia (certolizumab pegol) received approval for adults with moderate to severe Crohn's disease who have not responded to conventional therapies. This product was approved with a Medication Guide.

22 Apr 2008

Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients

For elderly and disabled rheumatoid arthritis (RA) sufferers, the Medicare Prescription Drug Improvement and Modernization Act (MMA) brought the promise of better disease management with "biologic" drugs.

15 Apr 2008

Stopping unwanted cell death: novel avenue for drug development

Research published in Nature Chemical Biology reveals that three specific inhibitors of a cell death pathway, termed necroptosis, all target and inhibit RIP1 kinase, a protein that can direct cells into necrosis.

13 Apr 2008

Traffic pollution exposure during first year of life leads to asthma, allergies and impaired respiratory function

Children exposed to high levels of air pollution during their first year of life run a greater risk of developing asthma, pollen allergies, and impaired respiratory function.

10 Apr 2008

Discovery of new genetic links to psoriasis

In the first comprehensive study of the genetic basis of psoriasis, researchers at Washington University School of Medicine in St. Louis have discovered seven new sites of common DNA variation that increase the risk of the troublesome skin condition.

4 Apr 2008

Discovery of new mechanism involved in inflammatory diseases

Investigators at Hospital for Special Surgery have identified a new mechanism involved in the pathogenesis of inflammatory diseases such as rheumatoid arthritis.

17 Mar 2008

Investigational drug Debio-025 tested for preventing muscle fiber death in muscular dystrophy

An investigational antiviral drug currently undergoing human trials in Europe for treating Hepatitis C infections may have potential to reduce muscle cell damage in Duchenne and other forms of muscular dystrophy (MD).

17 Mar 2008

Researchers find treatment for familial cold autoinflammatory syndrome

Dalhousie Medical School dermatologist Dr. Barrie Ross and his colleagues have successfully ended a 20-year quest to find a treatment for Familial Cold Autoinflammatory Syndrome (FCAS).

12 Mar 2008

Once-a-week arthritis pill significantly reduces the risk of heart attacks

A once-a-week pill to treat rheumatoid arthritis significantly reduces the risk of heart attack and stroke for people with the painful joint condition.

10 Mar 2008

Watery pools in bone marrow key to psoriatic arthritic damage

Researchers have learned more about how a leading drug prevents certain types of arthritis from eating away at bone, according to a study published in the March edition of the Annals of the Rheumatic Diseases.

4 Mar 2008

Effect of tumor necrosis factor a inhibitors on heart failure risk in rheumatoid arthritis

A chronic autoimmune disease, rheumatoid arthritis (RA) is characterized by persistent inflammation of the synovial membrane and progressive joint destruction.

28 Feb 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008